Devices/Safety Alert·openFDA/device

CLEARLINK/CONTINU-FLO/DUO-VENT (BAXTER HEALTHCARE CORPORATION) — Injury

MediumPublished Jul 31, 2026· AI-analyzed Aug 11, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

An injury event was reported involving the Clearlink, Continu-Flo, and Duo-Vent devices manufactured by Baxter Healthcare Corporation.

Who it affects

This affects Baxter Healthcare Corporation and personnel responsible for the safety monitoring of the Clearlink, Continu-Flo, and Duo-Vent IV administration products.

Why it matters

The report of an injury associated with these specific IV administration components necessitates a review of post-market surveillance data. It suggests that these devices may be undergoing increased regulatory scrutiny regarding their safety profiles or that a specific failure mode has resulted in patient harm, requiring verification of current risk controls.

Practical takeaway

Regulatory and QA teams should ensure current complaint handling procedures for these IV administration sets are aligned with the reported injury profile. Risk management files and IFUs should be reviewed to confirm that the reported event type is adequately covered under existing hazard analysis.

FDA source material

Event type: Injury. Device: CLEARLINK/CONTINU-FLO/DUO-VENT by BAXTER HEALTHCARE CORPORATION.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.